NUWE Nuwellis (NUWE) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001506492
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter
Nuwellis insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Nuwellis, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 4,098 shares held after it.
- No other insider bought within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Jaramillo Nestor Jr. bought about $19.6K of NUWE on Mar 15, 2023, the largest insider purchase at the company on our record; 3 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Medical Devices
Revenue
-5.4% year over year
below 83% of Medical Devices
Margin
-211.9% net margin
below 86% of Medical Devices
Buybacks
no share repurchases reported
Short interest
2.6% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-10-15
below 59% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NUWE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-97.1%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NUWE: institutional holders (13F)
13F holdings, latest reported quarter
16,372 sh
$49.9K
4,415 sh
$13.5K
$421
35 sh
$107
$12
Congress trades in NUWE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NUWE planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NUWE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$28.9K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$1.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Jaramillo
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$714.7K
$408.1K
$394.5K
n/a
n/a
2021
$1.1M
$659.1K
$412.9K
-96%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NUWE financials
Revenue growth
-5.4%
XBRL, annual
Net margin
-211.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NUWE
| FY Mar 2026 | $8.8M |
| FY Dec 2025 | $8.3M |
| FY Dec 2024 | $8.7M |
| FY Dec 2023 | $8.9M |
| FY Dec 2022 | $8.5M |
| Jun 2026 | $2.0M |
| Mar 2026 | $2.4M |
| Dec 2025 | $2.4M |
| Sep 2025 | $2.2M |
| Jun 2025 | $1.7M |
| Mar 2025 | $1.9M |
| Dec 2024 | $2.3M |
| Sep 2024 | $2.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-125.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NUWE
| FY Mar 2026 | -217.2% |
| FY Dec 2025 | -211.9% |
| FY Dec 2024 | -127.7% |
| FY Dec 2023 | -228.0% |
| FY Dec 2022 | -170.0% |
| Jun 2026 | -245.2% |
| Mar 2026 | -189.0% |
| Dec 2025 | -99.9% |
| Sep 2025 | +21.1% |
| Jun 2025 | -727.7% |
| Mar 2025 | -158.3% |
| Dec 2024 | -63.2% |
| Sep 2024 | +99.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | -$10.9M |
| FY Dec 2024 | -$9.7M |
| FY Dec 2023 | -$18.1M |
| FY Dec 2022 | -$15.3M |
| Jun 2026 | -$3.2M |
| Mar 2026 | -$3.1M |
| Dec 2025 | -$3.0M |
| Sep 2025 | -$3.2M |
| Jun 2025 | -$2.1M |
| Mar 2025 | -$2.5M |
| Dec 2024 | -$1.5M |
| Sep 2024 | -$2.5M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity NUWE
| FY Mar 2026 | -610.6% |
| FY Dec 2025 | -382.9% |
| FY Dec 2024 | -234.6% |
| FY Dec 2023 | -263.4% |
| FY Dec 2022 | -75.8% |
| Jun 2026 | n/a |
| Mar 2026 | -610.6% |
| Dec 2025 | -382.9% |
| Sep 2025 | -467.7% |
| Jun 2025 | n/a |
| Mar 2025 | -441.4% |
| Dec 2024 | -234.6% |
| Sep 2024 | -276.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-123.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NUWE
| FY Mar 2026 | -272.8% |
| FY Dec 2025 | -219.3% |
| FY Dec 2024 | -113.7% |
| FY Dec 2023 | -117.3% |
| FY Dec 2022 | -52.7% |
| Jun 2026 | -123.6% |
| Mar 2026 | -272.8% |
| Dec 2025 | -219.3% |
| Sep 2025 | -225.2% |
| Jun 2025 | -190.7% |
| Mar 2025 | -144.1% |
| Dec 2024 | -113.7% |
| Sep 2024 | -167.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-247.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NUWE
| FY Mar 2026 | -336.9% |
| FY Dec 2025 | -213.8% |
| FY Dec 2024 | -158.1% |
| FY Dec 2023 | -132.6% |
| FY Dec 2022 | -72.9% |
| Jun 2026 | -247.0% |
| Mar 2026 | -336.9% |
| Dec 2025 | -213.8% |
| Sep 2025 | -260.3% |
| Jun 2025 | -264.3% |
| Mar 2025 | -282.0% |
| Dec 2024 | -158.1% |
| Sep 2024 | -195.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | -10.8% |
| FY Dec 2024 | -0.1% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -10.8% |
| Sep 2025 | -8.9% |
| Jun 2025 | -0.6% |
| Mar 2025 | -0.2% |
| Dec 2024 | -0.1% |
| Sep 2024 | -0.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
PEG, trailing NUWE
| FY Mar 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-12 | 2024-12 | 2023-12 | |
|---|---|---|---|---|
| Revenue | n/a | $8.3M | $8.7M | $8.9M |
| Gross profit | n/a | $5.1M | $5.7M | $5.0M |
| Operating income | n/a | -$11.1M | -$11.0M | -$17.6M |
| Net income | n/a | -$17.5M | -$11.2M | -$20.2M |
| EPS (diluted) | n/a | -25.39 | -353.30 | -360.06 |
| Operating cash flow | n/a | -$10.8M | -$9.6M | -$17.9M |
| Cash | $2.1M | $1.1M | $5.1M | $3.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
NUWE Stock Sonar score 4/7 axes
Find similar shapesCompareNUWE ranks highest on risk and compliance (34th percentile) and growth (17th), and lowest on institutional and government (1st), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
